Epidemiological, Clinical, and Therapeutic Characteristics of Gestational Trophoblastic Disease in Eastern Madagascar: A Retrospective Study at a Tertiary Referral Center
Background: Gestational trophoblastic disease (GTD) comprises a spectrum of pregnancy-related disorders with marked geographical variation in incidence, being more frequent in low- and middle-income countries. Data from eastern Madagascar remain limited. Objective: To describe the epidemiological, clinical, paraclinical, and therapeutic characteristics of GTD managed at a tertiary referral hospital in eastern Madagascar. Methods: A retrospective descriptive study was conducted over a six-year period (January 2019 to December 2024) at the University Hospital Center of Analankininina Toamasina (CHUAT). All patients diagnosed with GTD based on histopathological findings and/or biological follow-up were included. Data were collected from medical records and analyzed using descriptive statistics. Results: A total of 53 cases of GTD were identified, including 42 hydatidiform moles and 11 cases of gestational trophoblastic neoplasia (GTN). The mean age was 29 ± 8.5 years, with a predominance of women aged 20 - 29 years. Vaginal bleeding was the most common presenting symptom (31/53). Initial serum human chorionic gonadotropin (hCG) levels exceeded 100,000 IU/L in 27 cases. According to FIGO scoring, 6 cases were classified as low risk and 5 as high risk. Uterine evacuation by curettage was performed in 41 patients. Chemotherapy was administered in all GTN cases. Complete remission was achieved in 41 patients, while 3 deaths were recorded. Subsequent pregnancy occurred in 13 patients. Conclusion: GTD remains a significant health concern in eastern Madagascar, often diagnosed at advanced stages. Despite resource limitations, favorable outcomes can be achieved with appropriate management. Strengthening early diagnosis, pathology services, and follow-up systems is essential to improving prognosis.
References
[1]
Ngan, H.Y.S., Seckl, M.J., Berkowitz, R.S., Xiang, Y., Golfier, F., Sekharan, P.K., et al. (2021) Diagnosis and Management of Gestational Trophoblastic Disease: 2021 Update. International Journal of Gynecology & Obstetrics, 155, 86-93. https://doi.org/10.1002/ijgo.13877
[2]
Gullo, G., Satullo, M., Conti, E., Ganduscio, S., Chitoran, E., Kozinszky, Z., et al. (2025) Gestational Trophoblastic Disease: Diagnostic and Therapeutic Updates in Light of Recent Evidence: A Literature Review. Medicina, 61, Article No. 1642. https://doi.org/10.3390/medicina61091642
[3]
Coyle, C., Short, D., Jackson, L., Sebire, N.J., Kaur, B., Harvey, R., et al. (2018) What Is the Optimal Duration of Human Chorionic Gonadotrophin Surveillance Following Evacuation of a Molar Pregnancy? A Retrospective Analysis on over 20,000 Consecutive Patients. Gynecologic Oncology, 148, 254-257. https://doi.org/10.1016/j.ygyno.2017.12.008
[4]
Berkowitz, R.S. and Goldstein, D.P. (2009) Molar Pregnancy. New England Journal of Medicine, 360, 1639-1645. https://doi.org/10.1056/nejmcp0900696
[5]
Randriamaroson, N., Razakanaivo, M., Andrianandrasana, N.O., Solofonirina, Z.A. and Rafaramino, F. (2020) Gestational Trophoblastic Neoplasia: Clinical and Therapeutic Profile in Madagascar. Open Journal of Obstetrics and Gynecology, 10, 946-956. https://doi.org/10.4236/ojog.2020.1070089
[6]
Felemban, A.A., Bakri, Y.N., Alkharif, H.A., Altuwaijri, S.M., Shalhoub, J. and Berkowitz, R.S. (1998) Complete Molar Pregnancy: Clinical Trends at King Fahad Hospital, Riyadh, Kingdom of Saudi Arabia. Journal of Reproductive Medicine, 43, 11-13.
[7]
Sebire, N.J., Foskett, M., Fisher, R.A., Rees, H., Seckl, M. and Newlands, E. (2002) Risk of Partial and Complete Hydatidiform Molar Pregnancy in Relation to Maternal Age. BJOG: An International Journal of Obstetrics & Gynaecology, 109, 99-102. https://doi.org/10.1111/j.1471-0528.2002.t01-1-01037.x
[8]
Moodley, M. and Marishane, T. (2005) Demographic Variables of Gestational Trophoblastic Disease in Kwazulu-Natal, South Africa. Journal of Obstetrics and Gynaecology, 25, 482-485. https://doi.org/10.1080/01443610500171102
[9]
United Nations (2019) Contraceptive Use by Method 2019: Data Booklet. United Nations.
[10]
Berkowitz, R.S. and Goldstein, D.P. (2012) Clinical Practice: Molar Pregnancy. The New England Journal of Medicine, 366, 921-932.
[11]
Lukinovic, N., Malovrh, E.P., Takac, I., Sobocan, M. and Knez, J. (2022) Advances in Diagnostics and Management of Gestational Trophoblastic Disease. Radiology and Oncology, 56, 430-439. https://doi.org/10.2478/raon-2022-0038
[12]
Chawla, T., Bouchard-Fortier, G., Turashvili, G., Osborne, R., Hack, K. and Glanc, P. (2023) Gestational Trophoblastic Disease: An Update. Abdominal Radiology, 48, 1793-1815. https://doi.org/10.1007/s00261-023-03820-5
[13]
Munyakarama, B., Koushik, A., Leduc, V., Healy-Profitós, J. and Auger, N. (2025) Association of Gestational Trophoblastic Disease with Subsequent Development of Non-Trophoblastic Cancer. International Journal of Gynecology & Obstetrics, 168, 1305-1311. https://doi.org/10.1002/ijgo.15976